Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $551.8 million.

  • Syndax Pharmaceuticals' Liabilities and Shareholders Equity rose 2958.61% to $551.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 2209.19%. This contributed to the annual value of $724.8 million for FY2024, which is 1826.39% up from last year.
  • According to the latest figures from Q3 2025, Syndax Pharmaceuticals' Liabilities and Shareholders Equity is $551.8 million, which was up 2958.61% from $596.1 million recorded in Q2 2025.
  • Over the past 5 years, Syndax Pharmaceuticals' Liabilities and Shareholders Equity peaked at $724.8 million during Q4 2024, and registered a low of $239.5 million during Q3 2021.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $449.7 million (2021), whereas its average is $462.1 million.
  • Per our database at Business Quant, Syndax Pharmaceuticals' Liabilities and Shareholders Equity skyrocketed by 16596.17% in 2021 and then skyrocketed by 612.71% in 2023.
  • Syndax Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $449.7 million in 2021, then increased by 10.58% to $497.2 million in 2022, then increased by 23.26% to $612.9 million in 2023, then grew by 18.26% to $724.8 million in 2024, then fell by 23.87% to $551.8 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $551.8 million for Q3 2025, versus $596.1 million for Q2 2025 and $640.7 million for Q1 2025.